The side effects of selinesol tablets will disappear in a few days

Selinexor (Selinexor) is an oral small molecule inhibitor of exportin 1 with activity in hematological and solid malignancies, including multiple myeloma and diffuse largeB-cell lymphoma. Side effects associated with selinesol include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. One study evaluated 437 patients with multiple myeloma treated with selinesol and assessed the kinetics of adverse events and the impact of supportive care measures.

Selinesol decreased platelets and neutrophils during the first treatment cycle, reaching a nadir between days 28 and 42. Platelet transfusions and thrombopoietin receptor agonists are effective in treating thrombocytopenia, and granulocyte colony-stimulating factor is effective in relieving neutropenia. Gastrointestinal side effects (nausea, vomiting, and diarrhea) are most common during the first 1-2 weeks of treatment. Nausea can be reduced with 5-HT3 antagonists and neurokinin 1 receptor antagonists, olanzapine, or campbetics; loperamide and bismuth subsalicylate can improve diarrhea. The major constitutional side effects of fatigue and decreased appetite can be managed with methylphenidate, megestrol, cannabinoids, or olanzapine, respectively. Hyponatremia is highly sensitive to sodium replacement. Selinisol has well-established adverse effects, which mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

In summary, selinesol is a novel anticancer therapy with side effects that are unique among myeloma drugs and are generally reversible with dose adjustment and supportive care. Clinical trials are ongoing to study earlier treatment regimens of selinesol as well as lower doses in combination with approved drugs, with the goal of maximizing efficacy and minimizing side effects.